Seven ways blended datasets accelerate drug development and unlock label expansion

Speed and precision in drug development are crucial. Yet traditional research approaches, which tend to focus on a narrow cross-section of patients, can often fail to capture the real-world factors that determine a drug’s true potential. That’s where blended datasets come in. By merging open and closed claims, mortality data, lab results and social determinants of health (SDOH) under a secure, tokenized framework, life sciences organizations can discover hidden insights, optimize label expansions and supercharge decision-making at every stage of the product lifecycle.

In this Guest Column, we explore seven key applications of research-ready, blended datasets demonstrating how life science companies can leverage these rich data assets to drive evidence generation, streamline study design, and accelerate healthcare innovation. For a deeper dive into this topic, the White Paper, "Using Research-Ready Data to Accelerate Clinical Research," offers further insights and practical examples.

Treatment strategies with tokenized real-world data (RWD)

Tokenization is key to the secure, privacy-preserving linkage of patient-level data from multiple sources. In a blended dataset framework, tokenization allows researchers to merge de-identified information from clinical, administrative, and even consumer-mediated sources. This comprehensive assembly of data enables personalized treatment strategies that adapt to the complexities of individual patient journeys.

How it works: merging multiple data streams

A robust blended data platform uses a wide range of RWD streams:

1. Claims Data – Offers insight into patient diagnoses, treatments and healthcare utilization patterns.
2. Lab Results – Provides clinical measures such as blood tests or imaging reports.
3. Mortality Data – Allows for the assessment of long-term survival trends and treatment effectiveness.
4. Social Determinants of Health (SDOH) – Adds context for socioeconomic, environmental and lifestyle factors that influence adherence and outcomes.
5. Genomic Information – Pinpoints biomarkers and genetic variations linked to specific diseases or therapeutic responses.

By mapping these data streams through a rigorous tokenization process, life science companies ensure they are building integrated, research-ready cohorts.

“This holistic view of the patient allows for sophisticated analyses, such as subgroup identification and comparative effectiveness research that spans beyond conventional trial protocols”.

These seven use cases describe how blended datasets can transform your drug development strategy and help you achieve label expansions that reflect real-world needs.

1. Uncover niche patient cohorts for targeted label expansion

When you connect multiple data streams: claims, lab values, mortality updates, SDOH, you get a 360-degree view of patient populations. These layered insights can reveal smaller demographics pockets or clinical areas where a therapy excels. Discovering those subgroups, perhaps individuals with a specific biomarker or certain social risk factors, can be the catalyst for a targeted label expansion that meets unmet clinical needs.

• Why it matters: Traditional clinical trials might inadvertently exclude these high-potential niche groups of patients. Blended data helps organizations develop precise hypotheses and bolster regulatory submissions with real-world evidence (RWE) of safety and efficacy in specific populations.

2. Strengthen post-market surveillance with real-time adverse event tracking

Post-approval safety monitoring doesn’t have to be reactive. With tokenized open and closed claims plus mortality data, sponsors can rapidly detect spikes in hospital admissions or changes in mortality rates connected to a newly launched drug.

• Why it matters: Early detection of adverse event trends can inform swift label modifications, risk mitigation plans and proactive communications with healthcare professionals, ultimately supporting both patient safety and regulatory confidence.

3. SDOH data to address barriers to adherence

SDOH can often be the hidden factor derailing otherwise promising therapies. Patients in rural areas, for instance, may struggle with transportation, while those in low-income neighborhoods might face cost-related challenges. Blended datasets give sponsors a window into these non-clinical barriers, facilitating more effective engagement strategies.

• Why it matters: By spotlighting adherence roadblocks and linking them to real-world claims outcomes, organizations can develop resources, such as patient education or financial support, which foster better treatment continuity and justify label updates that factor in real-world usage patterns.

4. Reduce time-to-insight with pre-certified, tokenized data

Data wrangling can eat up months of valuable research time. For Medical Affairs teams, having a research-ready dataset – where records are already tokenized and de-identified for HIPAA compliance – you can skip straight to analysis and understanding medical impact to better adjust label expansions as needed. Mortality, lab and claims data become seamlessly integrated, saving you the hassle of manually reconciling multiple sources.

• Why it matters: Faster time-to-insight means you can launch confirmatory studies or test new hypotheses almost immediately, refining your product pipeline or label expansions in real time.

5. Build a compelling economic case for label expansion

Drugs can’t just be clinically effective; they must also make economic sense for payers, providers and patients. Closed claims data shed light on cost drivers like hospital readmissions, while open claims and SDOH reveal the full spectrum of resource utilization.

• Why it matters: Armed with real-world numbers, you can craft a robust financial narrative illustrating that a new indication or recommended dosage not only helps more patients but also saves money in the long run. This resonates strongly with payers, making them more likely to support and reimburse an expanded label.

6. Advance clinical trials with real-world patient cohorts

Planning a successful clinical trial is part art, part science. By reviewing blended data before setting trial criteria, sponsors can choose patient populations that better reflect actual disease states and comorbidities. Perhaps you find that a significant portion of your target group has concurrent conditions; incorporating these realities into the study design will yield results that are more generalizable to the entire market.

• Why it matters: Trials enriched with RWD are more likely to predict real-world success when patient cohorts represent real-world patient populations. This lowers the risk of late-stage surprises, supports eventual label expansion and can align your product with the everyday challenges that physicians and patients face.

7. Improve resource utilization and build equity-focused interventions

A therapy’s efficacy can be overshadowed by poor resource allocation – like mismatched coverage networks, lack of specialist availability or patient adherence pitfalls. Blended datasets help you spot where resources are over- or under-utilized, enabling you to design interventions that expand access and equity.

• Why it matters: This data-backed approach shows regulators and advocacy groups that your organization cares about health equity, particularly in underserved populations. Demonstrating a therapy’s real-world impact on traditionally neglected communities can set the stage for a broader label that accounts for social and environmental factors impacting patient outcomes.

By using these seven tactics – and pairing them with tokenized, research-ready datasets – life science companies can respond more effectively to shifting market demands, achieve new label expansions and deliver more value to patients, providers and payers.

“Embracing blended data offers a meaningful step toward a future where real-world drug performance informs more responsive, evidence-based healthcare decisions.”

These seven strategies are just the beginning. If you want to see how blended datasets accelerate drug development and fuel label expansions in real-world scenarios, download the White Paper to explore real-world use cases and actionable strategies for leveraging blended data in your organization.

Sponsorship for this Guest Column was provided by LexisNexis® Risk Solutions

LexisNexis^® Risk Solutions harnesses the power of data, sophisticated analytics platforms and technology solutions, empowering healthcare researchers with critical insights to increase efficiencies, reduce inequities and create healthier communities.